-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $210

Benzinga·08/03/2026 21:25:06
語音播報
Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $210.